SEC Filing | Horizon Therapeutics plc

Date: August 8, 2023

HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY

/s/ Aaron L. Cox

Aaron L. Cox

Executive Vice President and Chief Financial Officer

View:

Download DOC

Download PDF

Download XLS

Download XBRL

8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 8, 2023

Horizon Therapeutics Public Limited Company

(Exact name of registrant as specified in its charter)

Ireland

001-35238

98-1195602

(State or other jurisdiction

of incorporation)

(Commission

File No.)

(IRS Employer

Identification No.)

70 St. Stephen’s Green, Dublin 2, D02 E2X4, Ireland

(Address of principal executive offices)

Registrant’s telephone number, including area code: 011-353-1-772-2100

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading

Symbol(s)

Name of each exchange

on which registered

Ordinary shares, nominal value $0.0001 per share

HZNP

The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On August 8, 2023, Horizon Therapeutics plc issued a press release announcing its financial results for the second quarter ended June 30, 2023. A copy of this press release is attached hereto as Exhibit 99.1.

Item 7.01 Regulation FD Disclosure.

Also on August 8, 2023, Horizon made available on its corporate website an investor presentation containing additional information about its business. A copy of this presentation is attached hereto as Exhibit 99.2 and the contents of the presentation are hereby incorporated by reference.

The information in Items 2.02 and 7.01 and the exhibits hereto are being furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.


Exhibit No.		Description

99.1		Press Release of Horizon Therapeutics plc, dated August 8, 2023.

99.2		Investor Presentation of Horizon Therapeutics plc, dated August 8, 2023.

104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

EX-99.1

Exhibit 99.1

LOGO

Horizon Therapeutics plc Reports Second-Quarter 2023 Financial Results

Second-Quarter 2023 Results:

— Net Sales of $945.0 Million, Representing Year-Over-Year Growth of 11%

Excluding Inflammation Medicines —

— GAAP Net Income of $127.1 Million; Adjusted EBITDA of $320.4 Million —

— TEPEZZA^® (teprotumumab-trbw) Net Sales of $445.5 Million —

— KRYSTEXXA^® (pegloticase injection) Net Sales of $244.3 Million —

— UPLIZNA^® (inebilizumab-cdon) Net Sales of $68.1 Million —

— Cash Position of $2.5 Billion as of June 30, 2023 —

Second-Quarter and Recent Company Highlights:

— Announced Positive Topline Data from TEPEZZA Phase 4 Clinical Trial in Patients with

Chronic/Low Clinical Activity Score (CAS) Thyroid Eye Disease (TED) —

— Obtained U.S. FDA Approval for Updated TEPEZZA Indication to Specify Treatment of

TED Patients Regardless of Disease Activity or Duration —

— Announced Positive Topline Data from TEPEZZA Phase 3 Clinical Trial (OPTIC-J) in Japanese Patients —

— Received Approval for TEPEZZA in Brazil for the Treatment of TED; First Country Outside the

U.S. to Approve TEPEZZA —

— Announced Initiation of TEPEZZA Phase 3 Clinical Trial in Chronic/Low CAS TED in Japan and

Daxdilimab Phase 2 Clinical Trial in Lupus Nephritis —

— Presented New Data from Dazodalibep Phase 2 Clinical Trial in Sjögren’s Syndrome and

KRYSTEXXA MIRROR Randomized Controlled Trial at EULAR European Congress of Rheumatology —

— Continue to Expect Amgen Transaction to Close by Mid-December, Assuming the

Federal Trade Commission’s Request for a Preliminary Injunction Is Denied —

— Named One of Fortune’s 100 Best Companies to Work For^® and Ranked as Top

Biotechnology/Pharmaceutical Company, Both for Third Consecutive Year —

— Ranked First in Overall Corporate Reputation by U.S. Patient Advocacy Groups —

DUBLIN – Aug. 8, 2023 – Horizon Therapeutics plc (Nasdaq: HZNP) today announced second-quarter 2023 financial results.

“We delivered strong growth in the second quarter, with double-digit year-over-year growth in our core business and mid-teens growth sequentially,” said Tim Walbert, chairman, president and chief executive officer, Horizon. “This performance was driven by exceptional 46% year-over-year KRYSTEXXA sales growth as a result of strong commercial execution and the success of our immunomodulation strategy, in addition to positive and consistent trends we are generating for TEPEZZA, which reflects the success of our expansion efforts to further penetrate the TED market and reach new prescribers. We delivered impressive 76% year-over-year UPLIZNA sales growth and see a long runway ahead as we progress our two Phase 3 programs in IgG4-RD and MG. We also announced several important clinical milestones for TEPEZZA, including strong data in low CAS and long-duration TED and data from our Phase 3 clinical trial in Japan, both of which we expect to contribute to the future growth of this medicine.”

LOGO

Financial Highlights


(in millions except for per share amounts and percentages)	Q2 23		Q2 22		% Change		YTD 23		YTD 22		% Change
Net sales	$	945.0	$	876.4		8	$	1,777.0	$	1,761.7		1
Net income		127.1		61.0		108		181.8		265.2		(31	)
Non-GAAP net income		280.1		253.8		10		474.4		569.6		(17	)
Adjusted EBITDA		320.4		306.6		4		553.3		677.8		(18	)

Earnings per share - diluted		0.54		0.26		108		0.78		1.12		(30	)
Non-GAAP earnings per share - diluted		1.20		1.07		12		2.03		2.41		(16	)

Second-Quarter and Year-to-Date 2023 Net Sales Results


(in millions except for percentages)	Q2 23		Q2 22		% Change			YTD 23		YTD 22		% Change
TEPEZZA^®	$	445.5	$	479.8		(7	)	$	850.8	$	981.3		(13	)
KRYSTEXXA^®		244.3		167.8		46			431.3		308.5		40
RAVICTI^®		88.4		75.7		17			178.7		154.1		16
UPLIZNA^®⁽¹⁾		68.1		38.6		76			121.9		69.1		76
PROCYSBI^®		53.1		47.7		11			103.6		97.3		7
ACTIMMUNE^®		29.0		30.0		(3	)		58.2		61.3		(5	)
PENNSAID 2%^®⁽²⁾		7.0		23.6		(70	)		16.1		59.0		(72	)
RAYOS^®		8.0		11.1		(28	)		13.0		24.6		(47	)
BUPHENYL^®		1.3		1.4		(10	)		2.6		3.5		(25	)
QUINSAIR^TM		0.3		0.3		3			0.6		0.6		1
DUEXIS^®		—		0.1		(100	)		0.1		1.2		(91	)
VIMOVO^®		—		0.3		(100	)		0.1		1.2		(91	)

Total Net Sales⁽³⁾	$	945.0	$	876.4		8		$	1,777.0	$	1,761.7		1

(1)	Second-quarter and year-to-date 2023 UPLIZNA net sales included $15.4 million and $22.0 million, respectively, in international net sales. Second-quarter and year-to-date 2022 UPLIZNA net sales included $8.6 million and $13.8 million, respectively, in international net sales.

(2)	On May 6, 2022, Apotex Inc. initiated an at-risk launch of generic PENNSAID 2% in the United States.

(3)	Excluding the Company’s inflammation business unit (RAYOS, PENNSAID 2%, DUEXIS and VIMOVO), which was wound down at the end of 2022 due to generic competition, second-quarter year-over-year net sales growth was 11%.

Key Growth Drivers

TEPEZZA: TEPEZZA net sales in the second quarter were $446 million, representing a 10% sequential increase compared to the first quarter of 2023 and a 7% year-over-year decline compared to the second quarter of 2022. The TEPEZZA field-force expansion initiated late in 2022 continues to drive consistent and positive momentum in the business, including increases in new prescribers, patient enrollment forms and patient starts. Through the first half of 2023, as a result of the field-force expansion, the Company expanded its reach to new physician targets, which led to a 50% year-over-year increase in the number of ophthalmologists and endocrinologists prescribing TEPEZZA. In line with the Company’s expansion strategy, prescriber growth has largely come from ophthalmologists, with continued strong referral volume from endocrinologists.

LOGO

In April 2023, the Company announced positive topline results from its TEPEZZA Phase 4 clinical trial in patients with low CAS and long-duration TED and received FDA approval for an update to the indication for TEPEZZA that supports its potential benefit in TED, regardless of disease activity or duration. The Company is executing on its payer strategy to educate key stakeholders and ease the access burden so all eligible patients can benefit from TEPEZZA. As a result of this process, large national and regional payers are beginning the process of updating their access requirements. To date, the Company has obtained favorable policy changes for greater than 20% of U.S. covered lives, which are expected to take effect in the second half of 2023. The Company expects these strategies and initiatives to further develop the TED market and impact net sales in 2024.

In addition, the Company made significant advancements in its global expansion strategy by announcing the positive topline results from its TEPEZZA Phase 3 clinical trial in Japanese patients, as well as the approval of TEPEZZA in Brazil for patients with TED. There are no medicines approved for the treatment of TED in Brazil or Japan, representing a significant unmet need in both markets. These accomplishments, which are expected to impact net sales beginning in 2025, are important milestones in the Company’s global expansion strategy to bring TEPEZZA to more patients worldwide.

KRYSTEXXA: KRYSTEXXA net sales in the second quarter were a record $244 million, representing a 31% sequential increase compared to the first quarter of 2023 and a 46% year-over-year increase compared to the second quarter of 2022. KRYSTEXXA net sales are now annualizing at a nearly one-billion-dollar run rate. The second-quarter results were driven by execution across all phases of the patient journey – demand generation, stakeholder education and adherence to treatment. The Company continued to see significant uptake from both its rheumatology and nephrology market segments in the quarter, with KRYSTEXXA with immunomodulation usage now at more than 70% of new patient starts. The Company’s efforts to educate physicians and key stakeholders continues to lead to strong patient growth from both new and existing prescribers across both market segments.

UPLIZNA: UPLIZNA net sales in the second quarter were a record $68 million, representing a 27% sequential increase compared to the first quarter of 2023 and a 76% year-over-year increase compared to the second quarter of 2022. Net sales in the U.S. were $53 million, an increase of 76% year-over-year, driven by strong commercial execution. The second-quarter results were driven by robust demand generation and new patient starts, increased depth among the Company’s existing prescribers and strong adherence to maintenance treatment. The Company continues to drive uptake among both patients naïve to biologics as well as patients switching from competitive biologic therapies, establishing UPLIZNA as the fastest-growing biologic in neuromyelitis optica spectrum disorder (NMOSD) year-to-date by market share. The Company expects to advance its global expansion strategy, with multiple planned international launches in 2023. The Company also continues to make progress on its two Phase 3 programs in IgG4-related disease (IgG4-RD) and myasthenia gravis (MG).

Conference Call

In light of the announced agreement to be acquired by Amgen Inc. and applicable securities laws, the Company will not be hosting a conference call to discuss its financial results. This earnings press release, investor deck and the related Quarterly Report on Form 10-Q for the quarter ended June 30, 2023 are publicly available in the Investor Relations section of the Company’s website at https://ir.horizontherapeutics.com.

LOGO

About Horizon

Horizon is a global biotechnology company focused on the discovery, development and commercialization of medicines that address critical needs for people impacted by rare, autoimmune and severe inflammatory diseases. Our pipeline is purposeful: we apply scientific expertise and courage to bring clinically meaningful therapies to patients. We believe science and compassion must work together to transform lives. For more information on how we go to incredible lengths to impact lives, visit www.horizontherapeutics.com and follow us on Twitter, LinkedIn, Instagram and Facebook.

Note Regarding Use of Non-GAAP Financial Measures

Horizon provides certain non-GAAP financial measures, including EBITDA, or earnings before interest, taxes, depreciation and amortization, adjusted EBITDA, non-GAAP net income, non-GAAP diluted earnings per share, non-GAAP gross profit and gross profit ratio, non-GAAP operating expenses, non-GAAP operating income, non-GAAP tax benefit (expense) and tax rate, non-GAAP operating cash flow and certain other non-GAAP income statement line items, each of which include adjustments to GAAP figures. These non-GAAP measures are intended to provide additional information on Horizon’s performance, operations, expenses, profitability and cash flows. Adjustments to Horizon’s GAAP figures exclude, as applicable, acquisition and/or divestiture-related costs, costs associated with our pending transaction with Amgen Inc., including responding to a second request review of the transaction by the United States Federal Trade Commission (the “FTC”) and subsequent lawsuit seeking to enjoin the transaction, manufacturing facility start-up costs, restructuring and realignment costs and gain on sale of asset, as well as non-cash items such as share-based compensation, inventory step-up expense, depreciation and amortization, non-cash interest expense, goodwill and long-lived assets impairment charges, gain (loss) on equity security investments and other non-cash adjustments. Certain other special items or substantive events may also be included in the non-GAAP adjustments periodically when their magnitude is significant within the periods incurred. Horizon maintains an established non-GAAP cost policy that guides the determination of what costs will be excluded in non-GAAP measures. Horizon believes that these non-GAAP financial measures, when considered together with the GAAP figures, can enhance an overall understanding of Horizon’s financial and operating performance. The non-GAAP financial measures are included with the intent of providing investors with a more complete understanding of the Company’s historical and expected financial results and trends and to facilitate comparisons between periods and with respect to projected information. In addition, these non-GAAP financial measures are among the indicators Horizon’s management uses for planning and forecasting purposes and measuring the Company’s performance. These non-GAAP financial measures should be considered in addition to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP. The non-GAAP financial measures used by the Company may be calculated differently from, and therefore may not be comparable to, non-GAAP financial measures used by other companies.

LOGO

Forward-Looking Statements

This press release contains forward-looking statements, including, but not limited to, statements related to the pending transaction with Amgen Inc., development, manufacturing and commercialization plans; expected timing of clinical trials and commercial launches; expected future milestones, pipeline expansions and regulatory approvals; potential market opportunities for, and benefits of, Horizon’s medicines and medicine candidates; expected impact of commercial strategies, clinical trial results and product label updates; and business and other statements that are not historical facts. These forward-looking statements are based on Horizon’s current expectations and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, whether the pending transaction with Amgen Inc. will be completed in a timely manner or at all, including whether the district court grants or denies the FTC’s request for a preliminary injunction; the parties’ ability to satisfy (or willingness to waive) the conditions to the consummation of the pending transaction with Amgen Inc., including with respect to the absence of orders preventing the consummation of the transaction; the effect of the pending transaction with Amgen Inc. on Horizon’s business relationships, operating results and business generally; risks that Horizon’s actual future financial and operating results may differ from its expectations or goals; Horizon’s ability to grow net sales from existing medicines; impacts of the on-going war between Russia and Ukraine; changes in inflation, interest rates and general economic conditions; the availability of coverage and adequate reimbursement and pricing from government and third-party payers; Horizon’s ability to successfully implement its business strategies, including the risks that its medicine growth and global expansion initiatives and strategies may not be successful and that new challenges to growth may arise in the future; risks inherent in developing novel medicine candidates and existing medicines for new indications; whether additional clinical trial results or data analyses will be consistent with preliminary results, results from other trials or Horizon’s expectations; risks associated with regulatory approvals; risks in the ability to recruit, train and retain qualified personnel; competition, including generic competition; the ability to protect intellectual property and defend patents; regulatory obligations and oversight, including any changes in the legal and regulatory environment in which Horizon operates and those risks detailed from time-to-time under the caption “Risk Factors” and elsewhere in Horizon’s filings and reports with the SEC. Horizon undertakes no duty or obligation to update any forward-looking statements contained in this press release as a result of new information.


Contacts:

Investors:		U.S. Media:

Tina Ventura		Geoff Curtis
Senior Vice President,		Executive Vice President,
Chief Investor Relations Officer		Corporate Affairs & Chief Communications Officer
investor-relations@horizontherapeutics.com		media@horizontherapeutics.com

Erin Linnihan
Executive Director,		Ireland Media:
Investor Relations		Eimear Rigby
investor-relations@horizontherapeutics.com		media@horizontherapeutics.com

LOGO

Horizon Therapeutics plc

Condensed Consolidated Statements of Operations (Unaudited)

(in thousands, except share and per share data)


	Three Months Ended June 30,						Six Months Ended June 30,
	2023			2022			2023			2022
Net sales	$	944,959		$	876,411		$	1,777,018		$	1,761,656
Cost of goods sold		219,958			230,216			428,521			445,278

Gross profit		725,001			646,195			1,348,497			1,316,378


OPERATING EXPENSES:
Research and development ⁽¹⁾		150,035			103,246			284,183			206,378
Selling, general and administrative		434,125			398,221			887,479			770,955
Impairment of goodwill		—			56,171			—			56,171
Gain on sale of asset		(2,000	)		—			(2,000	)		—

Total operating expenses		582,160			557,638			1,169,662			1,033,504

Operating income		142,841			88,557			178,835			282,874


OTHER EXPENSE, NET:
Interest expense, net		(12,098	)		(21,409	)		(27,638	)		(42,665	)
Foreign exchange gain		326			28			417			448
Other income (expense), net		4,183			(2,389	)		2,840			(3,131	)

Total other expense, net		(7,589	)		(23,770	)		(24,381	)		(45,348	)


Income before expense (benefit) for income taxes		135,252			64,787			154,454			237,526
Expense (benefit) for income taxes		8,181			3,813			(27,301	)		(27,709	)

Net income	$	127,071		$	60,974		$	181,755		$	265,235


Net income per ordinary share - basic	$	0.56		$	0.27		$	0.80		$	1.16


Weighted average ordinary shares outstanding - basic		228,743,143			230,020,004			228,571,356			229,559,715


Net income per ordinary share - diluted	$	0.54		$	0.26		$	0.78		$	1.12


Weighted average ordinary shares outstanding - diluted		233,935,591			236,166,384			233,938,149			236,077,147

(1)

Beginning with the third quarter of 2022, the Company is separately presenting upfront, milestone, and similar payments pursuant to collaborations, licenses of third-party technologies, and asset acquisitions as “Acquired in-process research and development and milestones” expenses in the condensed consolidated statement of comprehensive income. Amounts recorded in this line item would have historically been recorded to research and development (“R&D”) expenses. The Company believes the new classification assists users of the financial statements in better understanding the payments incurred to acquired in-process research and development, or IPR&D. Prior period consolidated statements of comprehensive income have been reclassified to conform with the new classification. There were no acquired IPR&D and milestones expenses during the three and six months ended June 30, 2023 and 2022.

LOGO

Horizon Therapeutics plc

Condensed Consolidated Balance Sheets (Unaudited)

(in thousands, except share data)


	As of
	June 30, 2023			December 31, 2022
ASSETS
CURRENT ASSETS:
Cash and cash equivalents	$	2,464,623		$	2,352,833
Restricted cash		4,791			4,755
Accounts receivable, net		717,417			676,347
Inventories, net		170,325			169,559
Prepaid expenses and other current assets		564,808			449,349

Total current assets		3,921,964			3,652,843

Property, plant and equipment, net		362,326			340,509
Developed technology and other intangible assets, net		2,486,565			2,664,777
In-process research and development		810,000			810,000
Goodwill		1,010,538			1,010,538
Deferred tax assets, net		444,306			431,814
Other long-term assets		263,042			204,135

Total assets	$	9,298,741		$	9,114,616

LIABILITIES AND SHAREHOLDERS’ EQUITY
CURRENT LIABILITIES:
Accounts payable	$	85,543		$	155,800
Accrued expenses and other current liabilities		496,669			457,557
Accrued trade discounts and rebates		319,469			319,780
Long-term debt—current portion		16,000			16,000

Total current liabilities		917,681			949,137

LONG-TERM LIABILITIES:
Long-term debt, net		2,541,458			2,546,837
Deferred tax liabilities, net		264,815			342,017
Other long-term liabilities		263,828			204,451

Total long-term liabilities		3,070,101			3,093,305

COMMITMENTS AND CONTINGENCIES
SHAREHOLDERS’ EQUITY:
Ordinary shares, $0.0001 nominal value; 600,000,000 shares authorized at June 30, 2023 and December 31, 2022; 229,323,393 and 227,625,913 shares issued at June 30, 2023 and December 31, 2022, respectively; and 228,939,027 and 227,241,547 shares outstanding at June 30, 2023 and December 31, 2022, respectively		23			23
Treasury stock, 384,366 ordinary shares at June 30, 2023 and December 31, 2022		(4,585	)		(4,585	)
Additional paid-in capital		4,522,145			4,474,199
Accumulated other comprehensive income		21,612			12,528
Retained earnings		771,764			590,009

Total shareholders’ equity		5,310,959			5,072,174

Total liabilities and shareholders’ equity	$	9,298,741		$	9,114,616

LOGO

Horizon Therapeutics plc

Condensed Consolidated Statements of Cash Flows (Unaudited)

(in thousands)


	Three Months Ended June 30,						Six Months Ended June 30,
	2023			2022			2023			2022
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income	$	127,071		$	60,974		$	181,755		$	265,235
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization expense		96,285			97,426			191,145			192,538
Equity-settled share-based compensation		60,271			45,149			118,391			92,449
Impairment of goodwill		—			56,171			—			56,171
Amortization of debt discount and deferred financing costs		1,308			2,327			2,779			3,904
Gain on sale of asset		(2,000	)		—			(2,000	)		—
Deferred income taxes		(4,642	)		30,864			(91,952	)		(3,032	)
Foreign exchange and other adjustments		(5,708	)		7,376			(6,143	)		10,566
Changes in operating assets and liabilities:
Accounts receivable		(92,670	)		11,152			(41,140	)		(40,513	)
Inventories		(5,833	)		22,818			(766	)		22,033
Prepaid expenses and other current assets		(60,191	)		(38,373	)		(108,816	)		(71,578	)
Accounts payable		7,807			(48,047	)		(70,233	)		(11,980	)
Accrued trade discounts and rebates		9,386			(27,047	)		(552	)		20,232
Accrued expenses and other current liabilities		20,532			36,874			63,390			(76,901	)
Other non-current assets and liabilities		9,851			(8,468	)		11,931			5,863

Net cash provided by operating activities		161,467			249,196			247,789			464,987

CASH FLOWS FROM INVESTING ACTIVITIES:
Payments for acquisitions, net of cash acquired		—			—			—			(3,122	)
Purchases of property, plant and equipment		(18,466	)		(10,154	)		(42,594	)		(24,352	)
Payments for long-term investments		(1,560	)		(6,443	)		(4,183	)		(4,847	)
Receipts from long-term investments		—			4,416			—			4,416
Payments related to license and collaboration agreements		—			—			(15,000	)		(25,000	)

Net cash used in investing activities		(20,026	)		(12,181	)		(61,777	)		(52,905	)

CASH FLOWS FROM FINANCING ACTIVITIES:
Repayment of term loans		(4,000	)		(4,000	)		(8,000	)		(8,000	)
Proceeds from the issuance of ordinary shares in conjunction with ESPP program		14,912			13,884			14,912			13,884
Proceeds from the issuance of ordinary shares in connection with stock option exercises		2,628			12,951			6,049			22,022
Payment of employee withholding taxes relating to share-based awards		(4,506	)		(5,419	)		(92,055	)		(120,527	)

Net cash provided by (used in) financing activities		9,034			17,416			(79,094	)		(92,621	)

Effect of foreign exchange rate changes on cash, cash equivalents and restricted cash		2,539			(4,396	)		4,908			(6,317	)

Net increase in cash, cash equivalents and restricted cash		153,014			250,035			111,826			313,144
Cash, cash equivalents and restricted cash, beginning of the period⁽¹⁾		2,316,400			1,647,265			2,357,588			1,584,156

Cash, cash equivalents and restricted cash, end of the period⁽¹⁾	$	2,469,414		$	1,897,300		$	2,469,414		$	1,897,300

(1)	Amounts include restricted cash balance in accordance with ASU No. 2016-18. Cash and cash equivalents excluding restricted cash are shown on the balance sheet.

LOGO

Horizon Therapeutics plc

GAAP to Non-GAAP Reconciliations

Net Income and Earnings Per Share (Unaudited)

(in thousands, except share and per share data)


	Three Months Ended June 30,						Six Months Ended June 30,
	2023			2022			2023			2022
GAAP net income	$	127,071		$	60,974		$	181,755		$	265,235
Non-GAAP adjustments:
Acquisition/divestiture-related costs		52			1,023			733			2,612
Transaction-related costs		16,539			—			26,323			—
(Gain) loss on equity security investments		(2,437	)		438			(2,789	)		5,084
Restructuring and realignment costs		854			1,253			2,676			1,790
Manufacturing facility start-up costs		1,896			1,582			5,372			2,389
Amortization and step-up:
Intangible amortization expense		89,598			91,335			178,212			180,595
Inventory step-up expense		1,572			17,362			31,315			44,563
Amortization of debt discount and deferred financing costs		1,308			2,327			2,779			3,904
Impairment of goodwill		—			56,171			—			56,171
Gain on sale of asset		(2,000	)		—			(2,000	)		—
Share-based compensation		60,271			45,149			118,391			92,449
Depreciation		6,687			6,091			12,933			11,943

Total of pre-tax non-GAAP adjustments		174,340			222,731			373,945			401,500
Income tax effect of pre-tax non-GAAP adjustments		(21,354	)		(29,919	)		(81,297	)		(97,131	)

Total of non-GAAP adjustments		152,986			192,812			292,648			304,369

Non-GAAP net income	$	280,057		$	253,786		$	474,403		$	569,604


Non-GAAP Earnings Per Share:
Weighted average ordinary shares - Basic		228,743,143			230,020,004			228,571,356			229,559,715


Non-GAAP Earnings Per Share - Basic:
GAAP earnings per share - Basic	$	0.56		$	0.27		$	0.80		$	1.16
Non-GAAP adjustments		0.66			0.83			1.28			1.32

Non-GAAP earnings per share - Basic	$	1.22		$	1.10		$	2.08		$	2.48


Weighted average ordinary shares - Diluted
Weighted average ordinary shares - Basic		228,743,143			230,020,004			228,571,356			229,559,715
Ordinary share equivalents		5,192,448			6,146,380			5,366,793			6,517,432

Weighted average ordinary shares - Diluted		233,935,591			236,166,384			233,938,149			236,077,147


Non-GAAP Earnings Per Share - Diluted
GAAP earnings per share - Diluted	$	0.54		$	0.26		$	0.78		$	1.12
Non-GAAP adjustments		0.66			0.81			1.25			1.29

Non-GAAP earnings per share - Diluted	$	1.20		$	1.07		$	2.03		$	2.41

LOGO

Horizon Therapeutics plc

GAAP to Non-GAAP Reconciliations

EBITDA and Adjusted EBITDA (Unaudited)

(in thousands)


	Three Months Ended June 30,					Six Months Ended June 30,
	2023			2022		2023			2022
GAAP net income	$	127,071		$	60,974	$	181,755		$	265,235
Depreciation		6,687			6,091		12,933			11,943
Amortization and step-up:
Intangible amortization expense		89,598			91,335		178,212			180,595
Inventory step-up expense		1,572			17,362		31,315			44,563
Interest expense, net (including amortization of debt discount and deferred financing costs)		12,098			21,409		27,638			42,665
Expense (benefit) for income taxes		8,181			3,813		(27,301	)		(27,709	)

EBITDA	$	245,207		$	200,984	$	404,552		$	517,292

Other non-GAAP adjustments:
Share-based compensation		60,271			45,149		118,391			92,449
(Gain) loss on equity security investments		(2,437	)		438		(2,789	)		5,084
Impairment of goodwill		—			56,171		—			56,171
Gain on sale of asset		(2,000	)		—		(2,000	)		—
Acquisition/divestiture-related costs		52			1,023		733			2,612
Transaction-related costs		16,539			—		26,323			—
Manufacturing facility start-up costs		1,896			1,582		5,372			2,389
Restructuring and realignment costs		854			1,253		2,676			1,790

Total of other non-GAAP adjustments		75,175			105,616		148,706			160,495

Adjusted EBITDA	$	320,382		$	306,600	$	553,258		$	677,787

LOGO

Horizon Therapeutics plc

GAAP to Non-GAAP Reconciliations

Operating Income (Unaudited)

(in thousands)


	Three Months Ended June 30,						Six Months Ended June 30,
	2023			2022			2023			2022
GAAP operating income	$	142,841		$	88,557		$	178,835		$	282,874
Non-GAAP adjustments:
Acquisition/divestiture-related costs		52			1,023			733			2,612
Transaction-related costs		16,539			—			26,323			—
Restructuring and realignment costs		854			1,253			2,676			1,790
Manufacturing facility start-up costs		1,896			1,582			5,372			2,389
Amortization and step-up:
Intangible amortization expense		89,598			91,335			178,212			180,595
Inventory step-up expense		1,572			17,362			31,315			44,563
Impairment of goodwill		—			56,171			—			56,171
Gain on sale of asset		(2,000	)		—			(2,000	)		—
Share-based compensation		60,271			45,149			118,391			92,449
Depreciation		6,687			6,091			12,933			11,943

Total of non-GAAP adjustments		175,469			219,966			373,955			392,512

Non-GAAP operating income	$	318,310		$	308,523		$	552,790		$	675,386


Foreign exchange gain		326			28			417			448
Other income (expense), net		1,746			(1,951	)		51			1,953

Adjusted EBITDA	$	320,382		$	306,600		$	553,258		$	677,787

LOGO

Horizon Therapeutics plc

GAAP to Non-GAAP Reconciliations

Gross Profit and Operating Cash Flow (Unaudited)

(in thousands, except percentages)


	Three Months Ended June 30,						Six Months Ended June 30,
	2023			2022			2023			2022
Non-GAAP Gross Profit:
GAAP gross profit	$	725,001		$	646,195		$	1,348,497		$	1,316,378
Non-GAAP gross profit adjustments:
Acquisition/divestiture-related costs		52			(119	)		20			(1,423	)
Intangible amortization expense		89,259			90,439			177,537			179,164
Inventory step-up expense		1,572			17,362			31,315			44,563
Share-based compensation		3,141			2,294			5,803			4,471
Depreciation		130			55			178			111

Total of Non-GAAP adjustments		94,154			110,031			214,853			226,886

Non-GAAP gross profit	$	819,155		$	756,226		$	1,563,350		$	1,543,264


GAAP gross profit %		76.7	%		73.7	%		75.9	%		74.7	%
Non-GAAP gross profit %		86.7	%		86.3	%		88.0	%		87.6	%

GAAP cash provided by operating activities	$	161,467		$	249,196		$	247,789		$	464,987
Cash payments for acquisition/divestiture-related costs		11			748			51			5,196
Cash payments for restructuring and realignment costs		931			570			5,572			1,144
Cash payments for manufacturing facility start-up costs		2,116			895			5,910			2,663
Cash payments for transaction-related costs		14,074			—			20,668			—

Non-GAAP operating cash flow	$	178,599		$	251,409		$	279,990		$	473,990

LOGO

Horizon Therapeutics plc

GAAP to Non-GAAP Tax Rate Reconciliation (Unaudited)

(in millions, except percentages and per share amounts)


	Q2 2023
	Pre-tax Net Income		Income Tax Expense		Tax Rate			Net Income		Diluted Earnings Per Share
As reported - GAAP	$	135.3	$	8.2		6.0	%	$	127.1	$	0.54
Non-GAAP adjustments		174.3		21.4					153.0

Non-GAAP	$	309.6	$	29.5		9.5	%	$	280.1	$	1.20


	Q2 2022
	Pre-tax Net Income		Income Tax Expense		Tax Rate			Net Income		Diluted Earnings Per Share
As reported - GAAP	$	64.8	$	3.8		5.9	%	$	61.0	$	0.26
Non-GAAP adjustments		222.7		29.9					192.8

Non-GAAP	$	287.5	$	33.7		11.7	%	$	253.8	$	1.07


	YTD 2023
	Pre-tax Net Income		Income Tax (Benefit) Expense			Tax Rate			Net Income		Diluted Earnings Per Share
As reported - GAAP	$	154.5	$	(27.3	)		(17.7	)%	$	181.8	$	0.78
Non-GAAP adjustments		373.9		81.3						292.6

Non-GAAP	$	528.4	$	54.0			10.2	%	$	474.4	$	2.03


	YTD 2022
	Pre-tax Net Income		Income Tax (Benefit) Expense			Tax Rate			Net Income		Diluted Earnings Per Share
As reported - GAAP	$	237.5	$	(27.7	)		(11.7	)%	$	265.2	$	1.12
Non-GAAP adjustments		401.5		97.1						304.4

Non-GAAP	$	639.0	$	69.4			10.9	%	$	569.6	$	2.41

LOGO

Horizon Therapeutics plc

Certain Income Statement Line Items - Non-GAAP Adjusted

For the Three Months Ended June 30, 2023 (Unaudited)

(in thousands)


	Cost of Goods			Research &			Selling, General			Gain on sale			Interest			Other Income			Income Tax
	Sold			Development			& Administrative			of asset			Expense, net			(Expense), net			Expense
GAAP as reported	$	(219,958	)	$	(150,035	)	$	(434,125	)	$	2,000		$	(12,098	)	$	4,183		$	(8,181	)
Non-GAAP Adjustments:
Acquisition/divestiture-related costs⁽¹⁾		52			—			—			—			—			—			—
Transaction-related costs⁽²⁾		—			—			16,539			—			—			—			—
Gain on equity security investments⁽³⁾		—			—			—			—			—			(2,437	)		—
Restructuring and realignment costs⁽⁴⁾		—			253			601			—			—			—			—
Manufacturing facility start-up costs⁽⁵⁾		—			—			1,896			—			—			—			—
Amortization and step-up:
Intangible amortization expense⁽⁶⁾		89,259			—			339			—			—			—			—
Inventory step-up expense⁽⁷⁾		1,572			—			—			—			—			—			—
Amortization of debt discount and deferred financing costs⁽⁸⁾		—			—			—			—			1,308			—			—
Gain on sale of asset⁽⁹⁾		—			—			—			(2,000	)		—			—			—
Share-based compensation⁽¹⁰⁾		3,141			9,395			47,735			—			—			—			—
Depreciation⁽¹¹⁾		130			588			5,969			—			—			—			—
Income tax effect on pre-tax non-GAAP adjustments⁽¹²⁾		—			—			—			—			—			—			(21,354	)

Total of non-GAAP adjustments		94,154			10,236			73,079			(2,000	)		1,308			(2,437	)		(21,354	)

Non-GAAP	$	(125,804	)	$	(139,799	)	$	(361,046	)	$	—		$	(10,790	)	$	1,746		$	(29,535	)

Horizon Therapeutics plc

Certain Income Statement Line Items - Non-GAAP Adjusted

For the Three Months Ended June 30, 2022 (Unaudited)

(in thousands)


	Cost of Goods			Research &			Selling, General			Impairment of			Interest			Other (Expense)			Income Tax
	Sold			Development			& Administrative			goodwill			Expense, net			Income, net			Expense
GAAP as reported	$	(230,216	)	$	(103,246	)	$	(398,221	)	$	(56,171	)	$	(21,409	)	$	(2,389	)	$	(3,813	)
Non-GAAP Adjustments:
Acquisition/divestiture-related costs⁽¹⁾		(119	)		—			1,142			—			—			—			—
Loss on equity security investments⁽³⁾		—			—			—			—			—			438			—
Restructuring and realignment costs⁽⁴⁾		—			804			449			—			—			—			—
Manufacturing facility start-up costs⁽⁵⁾		—			—			1,582			—			—			—			—
Amortization and step-up:
Intangible amortization expense⁽⁶⁾		90,439			—			896			—			—			—			—
Inventory step-up expense⁽⁷⁾		17,362			—			—			—			—			—			—
Amortization of debt discount and deferred financing costs⁽⁸⁾		—			—			—			—			2,327			—			—
Share-based compensation⁽¹⁰⁾		2,294			6,742			36,113			—			—			—			—
Depreciation⁽¹¹⁾		55			267			5,769			—			—			—			—
Impairment of goodwill⁽¹³⁾		—			—			—			56,171			—			—			—
Income tax effect on pre-tax non-GAAP adjustments⁽¹²⁾		—			—			—			—			—			—			(29,919	)

Total of non-GAAP adjustments		110,031			7,813			45,951			56,171			2,327			438			(29,919	)

Non-GAAP	$	(120,185	)	$	(95,433	)	$	(352,270	)	$	—		$	(19,082	)	$	(1,951	)	$	(33,732	)

LOGO

Horizon Therapeutics plc

Certain Income Statement Line Items - Non-GAAP Adjusted

For the Six Months Ended June 30, 2023 (Unaudited)

(in thousands)


	Cost of Goods Sold			Research & Development			Selling, General & Administrative			Gain on sale of asset			Interest Expense, net			Other Income (Expense), net			Income Tax Benefit (Expense)
GAAP as reported	$	(428,521	)	$	(284,183	)	$	(887,479	)	$	2,000		$	(27,638	)	$	2,840		$	27,301
Non-GAAP Adjustments:
Acquisition/divestiture-related costs⁽¹⁾		20			—			713			—			—			—			—
Transaction-related costs⁽²⁾		—			—			26,323			—			—			—			—
Gain on equity security investments⁽³⁾		—			—			—			—			—			(2,789	)		—
Restructuring and realignment costs⁽⁴⁾		—			50			2,626			—			—			—			—
Manufacturing facility start-up costs⁽⁵⁾		—			—			5,372			—			—			—			—
Amortization and step-up:
Intangible amortization expense⁽⁶⁾		177,537			—			675			—			—			—			—
Inventory step-up expense⁽⁷⁾		31,315			—			—			—			—			—			—
Amortization of debt discount and deferred financing costs⁽⁸⁾		—			—			—			—			2,779			—			—
Gain on sale of asset⁽⁹⁾		—			—			—			(2,000	)		—			—			—
Share-based compensation⁽¹⁰⁾		5,803			18,561			94,027			—			—			—			—
Depreciation⁽¹¹⁾		178			971			11,784			—			—			—			—
Income tax effect on pre-tax non-GAAP adjustments⁽¹²⁾		—			—			—			—			—			—			(81,297	)

Total of non-GAAP adjustments		214,853			19,582			141,520			(2,000	)		2,779			(2,789	)		(81,297	)

Non-GAAP	$	(213,668	)	$	(264,601	)	$	(745,959	)	$	—		$	(24,859	)	$	51		$	(53,996	)

Horizon Therapeutics plc

Certain Income Statement Line Items - Non-GAAP Adjusted

For the Six Months Ended June 30, 2022 (Unaudited)

(in thousands)


	Cost of Goods Sold			Research & Development			Selling, General & Administrative			Impairment of goodwill			Interest Expense, net			Other (Expense) Income, net			Income Tax Benefit (Expense)
GAAP as reported	$	(445,278	)	$	(206,378	)	$	(770,955	)	$	(56,171	)	$	(42,665	)	$	(3,131	)	$	27,709
Non-GAAP Adjustments:
Acquisition/divestiture-related costs⁽¹⁾		(1,423	)		2,000			2,035			—			—			—			—
Loss on equity security investments⁽³⁾		—			—			—			—			—			5,084			—
Restructuring and realignment costs⁽⁴⁾		—			804			986			—			—			—			—
Manufacturing facility start-up costs⁽⁵⁾		—			—			2,389			—			—			—			—
Amortization and step-up:
Intangible amortization expense⁽⁶⁾		179,164			—			1,431			—			—			—			—
Inventory step-up expense⁽⁷⁾		44,563			—			—			—			—			—			—
Amortization of debt discount and deferred financing costs⁽⁸⁾		—			—			—			—			3,904			—			—
Impairment of goodwill⁽¹³⁾		—			—			—			56,171			—			—			—
Share-based compensation⁽¹⁰⁾		4,471			15,720			72,258			—			—			—			—
Depreciation⁽¹¹⁾		111			493			11,339			—			—			—			—
Income tax effect on pre-tax non-GAAP adjustments⁽¹²⁾		—			—			—			—			—			—			(97,131	)

Total of non-GAAP adjustments		226,886			19,017			90,438			56,171			3,904			5,084			(97,131	)

Non-GAAP	$	(218,392	)	$	(187,361	)	$	(680,517	)	$	—		$	(38,761	)	$	1,953		$	(69,422	)

LOGO

NOTES FOR CERTAIN INCOME STATEMENT LINE ITEMS - NON-GAAP

1.	Primarily represents transaction and integration costs, including, advisory, legal, consulting and certain employee-related costs, incurred in connection with our acquisitions and divestitures.

Primarily represents transaction-related costs, including, advisory, legal, consulting and field-based employee retention costs, incurred in connection with the transaction with Amgen. The legal costs include costs incurred in responding to the FTC’s second request and subsequent lawsuit seeking to enjoin the transaction.

We held investments in equity securities with readily determinable fair values of $9.8 million and $8.1 million as of June 30, 2023 and 2022, respectively, which are included in other long-term assets in the condensed consolidated balance sheet. For the three and six months ended June 30, 2023, we recognized net unrealized gains of $2.4 million and $2.8 million, respectively, due to the change in fair value of these securities.

4.	Primarily represents severance and consulting costs related to the wind down of our former inflammation business during 2022 and rent and maintenance charges as a result of vacating the leased Lake Forest office in the first quarter of 2021.

During the three months ended June 30, 2023 and 2022, we recorded $1.9 million and $1.6 million, respectively, and $5.4 million and $2.4 million for the six months ended June 30, 2023 and 2022, respectively, of manufacturing facility start-up costs related to our drug product biologics manufacturing facility in Waterford, Ireland.

6.	Intangible amortization expenses are primarily associated with our developed technology related to TEPEZZA, KRYSTEXXA, RAVICTI, UPLIZNA, PROCYSBI, ACTIMMUNE, RAYOS and BUPHENYL.

During the three and six months ended June 30, 2023, we recognized in cost of goods sold $1.6 million and $31.3 million, respectively, for inventory step-up expense related to UPLIZNA inventory revalued in connection with the Viela Bio, Inc. acquisition. We recorded $17.4 million and $44.6 million of UPLIZNA inventory step-up expense in cost of goods sold during the three and six months ended June 30, 2022, respectively. Because inventory step-up expense is related to an acquisition, will not continue indefinitely and has a significant effect on our gross profit, gross margin percentage and net income for all affected periods, we exclude inventory step-up expense from our non-GAAP financial measures.

8.	Represents amortization of debt discount and deferred financing costs associated with our debt.

9.	During the six months ended June 30, 2023, gain on sale of asset represents a $2.0 million contingent consideration payment related to the sale of MIGERGOT in 2019. The contingent consideration payment was triggered during the second quarter of 2023 and it was received in July 2023.

LOGO

10.	Represents share-based compensation expense associated with restricted stock unit and performance stock unit grants to our employees and non-employee directors, and our employee share purchase plan.

11.	Represents depreciation expense related to our property, plant, equipment, software and leasehold improvements.

12.	Income tax adjustments on pre-tax non-GAAP adjustments represent the estimated income tax impact of each pre-tax non-GAAP adjustment based on the statutory income tax rate of the applicable jurisdictions for each non-GAAP adjustment.

13.

Our interim goodwill impairment test in the second quarter of 2022 indicated an impairment which represented the difference between the estimated fair value of the former inflammation reporting unit and its carrying value. As a result, we recognized an impairment charge of $56.2 million in June 2022 representing the full amount of goodwill for the former inflammation reporting unit.

EX-99.2

Investor Presentation Horizon Therapeutics plc August 2023 Exhibit 99.2

Forward-Looking Statements This presentation contains forward-looking statements, including, but not limited to, statements related to the pending transaction with Amgen Inc., development, manufacturing and commercialization plans; expected timing of clinical trials and commercial launches; expected future milestones, pipeline expansions and regulatory approvals; potential market opportunities for, and benefits of, Horizon’s medicines and medicine candidates; expected impact of commercial strategies, clinical trial results and product label updates; and business and other statements that are not historical facts. These forward-looking statements are based on Horizon’s current expectations and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, whether the pending transaction with Amgen Inc. will be completed in a timely manner or at all, including whether the district court grants or denies the FTC’s request for a preliminary injunction; the parties’ ability to satisfy (or willingness to waive) the conditions to the consummation of the pending transaction with Amgen Inc., including with respect to the absence of orders preventing the consummation of the transaction; the effect of the pending transaction with Amgen Inc. on Horizon’s business relationships, operating results and business generally; risks that Horizon’s actual future financial and operating results may differ from its expectations or goals; Horizon’s ability to grow net sales from existing medicines; impacts of the on-going war between Russia and Ukraine; changes in inflation, interest rates and general economic conditions; the availability of coverage and adequate reimbursement and pricing from government and third-party payers; Horizon’s ability to successfully implement its business strategies, including the risks that its medicine growth and global expansion initiatives and strategies may not be successful and that new challenges to growth may arise in the future; risks inherent in developing novel medicine candidates and existing medicines for new indications; whether additional clinical trial results or data analyses will be consistent with preliminary results, results from other trials or Horizon’s expectations; risks associated with regulatory approvals; risks in the ability to recruit, train and retain qualified personnel; competition, including generic competition; the ability to protect intellectual property and defend patents; regulatory obligations and oversight, including any changes in the legal and regulatory environment in which Horizon operates and those risks detailed from time-to-time under the caption "Risk Factors" and elsewhere in Horizon’s filings and reports with the SEC. Horizon undertakes no duty or obligation to update any forward-looking statements contained in this presentation as a result of new information. In light of the announced agreement to be acquired by Amgen Inc. and applicable securities laws, Horizon is not providing forward-looking financial guidance in this presentation.

Presentation At-A-Glance 1 2 3 4 5 6 Horizon Overview and 2Q23 Financial Results TEPEZZA® (teprotumumab-trbw) for Thyroid Eye Disease (TED) KRYSTEXXA® (pegloticase injection) for Uncontrolled Gout UPLIZNA® (inebilizumab-cdon) for NMOSD Our Pipeline Rare Disease Medicines, Intellectual Property and ESG NMOSD: Neuromyelitis optica spectrum disorder. | ESG: Environmental, social and governance.

Horizon is a Leading High-Growth, Innovation-Driven, Profitable, Global Biotech Portfolio of Key Rare, Autoimmune and Severe Inflammatory Medicines About Horizon 2022 Net Sales: $3.63 Billion 2022 Adj. EBITDA: $1.37 Billion Cash Position: $2.5 Billion as of June 30, 2023 Employees: >2,000 Global HQ: Dublin, Ireland; U.S. HQ: Deerfield, IL >20 pipeline programs across all stages of clinical development EBITDA: Earnings before interest, taxes, depreciation, and amortization. Adjusted EBITDA is a non-GAAP measure; see reconciliations at the end of the presentation for a reconciliation of GAAP to non-GAAP measures.

Executing on our Strategy TEPEZZA for the treatment of TED through our field-force expansion, education on low CAS clinical data/updated indication and global expansion KRYSTEXXA for the treatment of uncontrolled gout through our immunomodulation strategy and lifecycle management UPLIZNA for the treatment of NMOSD through education of its differentiated profile and future indications Maximizing the Value of our Key Growth Drivers Expanding our Pipeline for Sustainable Growth Building a Global Presence Announced positive topline data from TEPEZZA Phase 4 clinical trial in chronic/low CAS TED patients Advancing dazodalibep into Phase 3 in Sjögren’s syndrome following strong Phase 2 results Expect topline data from UPLIZNA Phase 3 clinical trials in IgG4-RD and MG in 2024 Received approval for TEPEZZA in Brazil; first country outside the U.S. to approve TEPEZZA Announced positive topline data from TEPEZZA Phase 3 clinical trial in Japanese patients (OPTIC-J); initiated Phase 3 clinical trial in chronic/ low CAS Japanese patients Continue to advance global expansion strategy for UPLIZNA with multiple planned international launches in 2023 TED: Thyroid eye disease. | NMOSD: Neuromyelitis Optica Spectrum Disorder. | CAS: Clinical activity score. | IgG4-RD: Immunoglobulin G4-Related Disease. | MG: Myasthenia gravis.

Amgen to Acquire Horizon Announced on December 12, 2022 Together, the two companies can serve many more patients impacted by rare, autoimmune and severe inflammatory diseases Amgen brings scale, experience and resources to maximize the value of Horizon’s current portfolio and pipeline and accelerates the ability to reach more patients globally The transaction has been approved by regulators around the world, apart from the U.S. Federal Trade Commission (FTC) The companies continue to expect the transaction to close by mid-December, assuming the FTC’s request for a preliminary injunction is denied The two companies continue to work closely on integration plans

Second-Quarter and Year-to-Date 2023 Financial Results ($M, except for per share amounts and percentages) Q2 2023 Q2 2022 % Change YTD 2023 YTD 2022 % Change Net sales $945.0 $876.4 8 $1,777.0 $1,761.7 1 Net Income 127.1 61.0 108 181.8 265.2 (31) Non-GAAP net income 280.1 253.8 10 474.4 569.6 (17) Adjusted EBITDA 320.4 306.6 4 553.3 677.8 (18) Earnings per share – diluted 0.54 0.26 108 0.78 1.12 (30) Non-GAAP earnings per share – diluted 1.20 1.07 12 2.03 2.41 (16) EBITDA: Earnings before interest, taxes, depreciation and amortization. | Note: Non-GAAP net income, adjusted EBITDA and non-GAAP earnings per share diluted are non-GAAP measures; see reconciliations at the end of the presentation for a reconciliation of GAAP to non-GAAP measures.

Second-Quarter and Year-to-Date 2023 Net Sales Results ($M) Q2 2023 Q2 2022 % Change YTD 2023 YTD 2022 % Change TEPEZZA® $445.5 $479.8 (7) $850.8 $981.3 (13) KRYSTEXXA® 244.3 167.8 46 431.3 308.5 40 RAVICTI® 88.4 75.7 17 178.7 154.1 16 UPLIZNA®(1) 68.1 38.6 76 121.9 69.1 76 PROCYSBI® 53.1 47.7 11 103.6 97.3 7 ACTIMMUNE® 29.0 30.0 (3) 58.2 61.3 (5) PENNSAID 2%®(2) 7.0 23.6 (70) 16.1 59.0 (72) RAYOS® 8.0 11.1 (28) 13.0 24.6 (47) BUPHENYL® 1.3 1.4 (10) 2.6 3.5 (25) QUINSAIRTM 0.3 0.3 3 0.6 0.6 1 DUEXIS® - 0.1 (100) 0.1 1.2 (91) VIMOVO® - 0.3 (100) 0.1 1.2 (91) Total Net Sales(3) $945.0 $876.4 8 $1,777.0 $1,761.7 1 (1) Second-quarter and year-to-date 2023 UPLIZNA net sales included $15.4 million and $22.0 million, respectively, in international net sales. Second-quarter and year-to-date 2022 UPLIZNA net sales included $8.6 million and $13.8 million, respectively, in international net sales. (2) On May 6, 2022, Apotex Inc. initiated an at-risk launch of generic PENNSAID 2% in the United States. (3) Excluding the Company’s inflammation business unit (RAYOS, PENNSAID 2%, DUEXIS and VIMOVO), which was wound down at the end of 2022 due to generic competition, second-quarter year-over-year net sales growth was 11%.

Presentation At-A-Glance 1 2 3 4 5 6 Horizon Overview and 2Q23 Financial Results TEPEZZA KRYSTEXXA UPLIZNA Our Pipeline Rare Disease Medicines, Intellectual Property and ESG ESG: Environmental, social and governance.

TED and How TEPEZZA Works TEPEZZA is the First and Only Medicine Approved for Thyroid Eye Disease (TED) Regardless of Disease Activity or Duration Rare, serious, progressive and vision-threatening autoimmune disease Causes proptosis (eye bulging); associated with diplopia (double-vision); painful and disfiguring TED presents with highly variable signs, symptoms and activity levels (CAS) that differ from patient to patient TEPEZZA decreases proptosis, improves diplopia, provides relief from eye pain/redness/swelling and improves functional vision/patient appearance TEPEZZA blocks IGF-1R and turns off signaling complex at the source of the disease IGF-1R: Insulin-like growth factor 1 receptor. | CAS: Clinical activity score. | The Phase 4 trial evaluated patients with an initial diagnosis of TED between two to 10 years (mean duration of 5.2 years; SD 1.77) and low levels of disease activity (mean CAS of 0.4; SD 0.49). The results represent the pre-specified primary analysis method (intent-to-treat). In the pre-specified per-protocol analysis, the differences between TEPEZZA and placebo increased. Proptosis response is defined as a reduction of ≥2 mm at Week 24. TEPEZZA Has Shown Clinical Benefit Across a Broad Spectrum of TED Patients High CAS TED Patients Low CAS TED Patients Phase 3 Proptosis Responders (%) p<0.001 (n=42) (n=41) (n=20) (n=42) Phase 4 Proptosis Responders (%) p=0.0134

Growth Strategy: Drive Strong Uptake and Expand TEPEZZA to More Patients Expand to new prescribers, including ophthalmologists and endocrinologists, to reach patients earlier in their TED journey 1 Educate stakeholders on new clinical data and updated indication to drive uptake across full spectrum of TED patients 2 Maximize the potential of TEPEZZA through global expansion and subcutaneous program 3 Executing on TEPEZZA Growth Strategy is Driving Consistent and Positive Momentum TEPEZZA Second-Quarter Performance Net sales of $446M, representing a quarter-over-quarter increase of 10% Expanded reach to new physician targets, which has led to a 50% year-over-year increase in the number of ophthalmologists and endocrinologists prescribing TEPEZZA (1H23 vs. 1H22) Prescriber growth has largely come from ophthalmologists, with continued strong referral volume from endocrinologists To date, obtained favorable policy changes for greater than 20% of U.S. covered lives, which are expected to take effect in 2H23 CAS: Clinical activity score. | TED: Thyroid eye disease.

U.S. TED Market Estimates(1) (1) Horizon estimates. | CAS: Clinical activity score. Expanded Field Force to Increase Breadth of Prescribers and Further Penetrate U.S. Thyroid Eye Disease (TED) Market Expansion Actions and Early Results >100K moderate-to-severe patients appropriate for TEPEZZA ~20% high CAS; ~80% low CAS ~One-third of addressable patients are seen by ocular specialists (~2,000 physician targets) ~Two-thirds of addressable patients are seen by ophthalmologists and endocrinologists (~10,000 physician targets) Increased the size of our field force to better support ocular specialists and enable more time for engagement and education Broadened our reach to ophthalmologists and endocrinologists to better educate them on TED and TEPEZZA 50% year-over-year increase in the number of ophthalmologists and endocrinologists prescribing TEPEZZA (1H23 vs. 1H22) Continue to drive urgency to diagnose and refer patients to a TEPEZZA prescriber Increased the breadth of physician targets to 12,000 Improved patient services model to better support patient access Increased education on medical co-management

Educating Stakeholders on New Phase 4 Clinical Data in Low CAS Thyroid Eye Disease (TED) Phase 4 Data and Updated Indication Are Important Milestones for the Long-Term Growth of TEPEZZA In 2Q23, generated impressive data in low CAS and long-duration TED patients In 2Q23, obtained U.S. FDA approval for updated indication to specify treatment of TED patients regardless of disease activity or duration Educating key stakeholders, including physicians, patients and payers on the trial results and updated label indication To date, obtained favorable policy changes for >20% of U.S. covered lives, which are expected to take effect in 2H23 Expect contribution from these initiatives to impact net sales in 2024 CAS: Clinical activity score. | The Phase 4 trial evaluated patients with an initial diagnosis of TED between two to 10 years (mean duration of 5.2 years; SD 1.77) and low levels of disease activity (mean CAS of 0.4; SD 0.49). Chronic/Low CAS Phase 4 Trial: Proptosis Response (Reduction of ≥2 mm) at Week 24 Per Protocol Intent-to-Treat p=0.0134 n= 20 | 42 p=0.0008 n= 14 | 30 Proptosis Responders (%)

TEPEZZA Clinical Data Provides an Opportunity to Address the Significant Unmet Need in Targeted International Markets Global Expansion of TEPEZZA Can Provide Long Runway for Growth OPTIC-J Phase 3 Trial: Proptosis Response (Reduction of ≥2 mm) at Week 24 TEPEZZA n=27 n=27 Placebo p<0.0001 89% 11% Proptosis Responders (%) Announced positive topline data from TEPEZZA Phase 3 clinical trial (OPTIC-J) in Japanese patients Initiated Phase 3 clinical trial for chronic/low CAS TED patients in Japan Received approval for TEPEZZA in Brazil for the treatment of TED; first country outside the U.S. to approve TEPEZZA Expect contribution from our global expansion to impact net sales beginning in 2025 CAS: Clinical activity score. | TED: Thyroid eye disease.

KRYSTEXXA is the First and Only Medicine Approved For Uncontrolled Gout Uncontrolled Gout and How KRYSTEXXA Works Gout is the most common inflammatory arthritis; systemic disease with multiple co-morbidities Uncontrolled gout is unresponsive to conventional therapies; associated with painful flares and tophi 9.5M U.S. gout patients; growing low-single digits(1); >100K uncontrolled gout patients(2) KRYSTEXXA rapidly reverses disease progression(3) Converts urate, the source of uric acid crystals, into a water-soluble substance, allantoin (1) Prevalence of gout and hyperuricemia in the U.S. general population: The National Health and Nutrition Examination Survey (NHANES) 2007-2016. Arthritis Rheum. 2019 Jun;71(6):991-999. (2) Approximate number of patients in our annual addressable target market in rheumatology and nephrology; Horizon estimate. (3) Sundy JS, Baraf HSB, Yood RA, et al. Efficacy and Tolerability of Pegloticase for the Treatment of Chronic Gout in Patients. Uncontrolled gout: Chronic gout refractory (unresponsive) to conventional therapies. | sUA: Serum uric acid. Baseline Week 14 Week 36 Week 52 Uncontrolled Gout Patient Treated with KRYSTEXXA

Growth Strategy: Increase Total Patients and Vials Per Patient Redefine KRYSTEXXA with methotrexate as the standard of care 1 Expand utilization in core specialty areas through field force expansion; elevate urgency to treat 2 Invest to improve the patient experience through faster infusion and monthly dosing options 3 Commercial Execution and Successful Immunomodulation Strategy Driving Growth KRYSTEXXA Second-Quarter Performance Record net sales of $244M, representing a year-over-year increase of 46% Strong results were driven by execution across all phases of the patient journey – demand generation, stakeholder education and adherence to treatment Continue to see strong uptake from rheumatology and nephrology market segments KRYSTEXXA with immunomodulation usage now at more than 70% of new patient starts

Our Immunomodulation Strategy is Driving Increased Uptake and Time on Therapy Responder rate defined by patients achieving and maintaining sUA <6 mg/dL for at least 80% of the time. Tophi resolution was defined as 100% resolution of at least 1 target tophus, no new tophi appearing, and no single tophus showing progression. (1) Horizon analysis of Hub and claims data of KRYSTEXXA-treated patients also receiving immunomodulators. | RCT: Randomized controlled trial. | sUA: Serum uric acid. | Pbo: Placebo. | MTX: Methotrexate. >70% Use of Immunomodulation with KRYSTEXXA(1) Patient Mix Has Rapidly Shifted Towards Use of KRYSTEXXA with Immunomodulation Key Benefits of Methotrexate Usage: Improves efficacy Reduced infusion reactions Improved confidence in the benefit/risk profile leading to more patients getting on therapy and staying on longer KRYSTEXXA Approved to be Prescribed with Methotrexate Supported by MIRROR RCT Responder Rate at Month 6 Tophi Resolution at Month 12 Infusion Reactions at Month 12

UPLIZNA Provides Targeted, Rapid, and Sustained CD19+ B-Cell Depletion; Approved in AQP4+ NMOSD NMOSD and How UPLIZNA Works Rare, autoimmune disease that attacks the optic nerve and spinal cord and can result in blindness, paralysis and death ~10K diagnosed NMOSD patients in the U.S.; ~8K AQP4+(1); ~400 new diagnoses each year(1) Humanized, affinity-optimized, glycoengineered monoclonal antibody that targets CD19+ B cells High efficacy; ~90% of clinical trial patients were attack-free at end of control period Safety and tolerability profile similar to placebo Convenient dosing with two doses per year, after loading doses NMOSD: Neuromyelitis optica spectrum disorder. | CD: Cluster of differentiation. | AQP4+: Aquaporin-4 positive. | (1) Horizon estimate. Phase 3 Data: UPLIZNA Reduced Risk of NMOSD Attacks, Disability Accumulation and Hospitalization 88% 57% Attack-Free Probability AQP4-IgG seropositive population Days to Attack Placebo UPLIZNA 9 OUT OF 10 patients were attack-free at end of control period

Growth Drivers: Transition Existing Patients and Drive Uptake in New Patients Drive awareness and understanding of UPLIZNA’s comprehensive benefits and differentiated clinical profile 1 Drive patient initiation and adherence; cultivate a positive patient experience 2 Maximize the potential of UPLIZNA through additional indications and global expansion 3 UPLIZNA on a Strong Growth Trajectory UPLIZNA Second-Quarter Performance Record net sales of $68M, representing a year-over-year increase of 76% Results were driven by robust demand generation and new patient starts, increased depth among our existing prescribers and strong adherence to maintenance treatment Continued to drive uptake among both patients naïve to biologics as well as patients switching from competitive biologic therapies, establishing UPLIZNA as the fastest-growing biologic in NMOSD year-to-date by market share

IgG4: Immunoglobulin G4. | TED: Thyroid eye disease. CAS: Clinical activity score. (1) Announced positive Phase 2 topline results for patients with moderate-to-severe systemic disease activity and moderate-to-severe symptomatology on Sep. 12, 2022, and Jan. 18, 2023, respectively. Both trials met the primary endpoint and dazodalibep was well tolerated. (2) Planned programs; not yet initiated. (3) Announced topline results on July 21, 2023. The trial did not meet the primary endpoint; numerical differences were seen in other endpoints; no safety concerns were reported. (4) Horizon has an option to acquire ADX-914 from Q32 Bio on pre-negotiated terms through the completion of Phase 2 clinical trials. Phase 2 trials to be conducted by Q32. (5) External collaborations. Our Pipeline is Focused on Rare, Autoimmune and Severe Inflammatory Diseases UPLIZNA Myasthenia Gravis (MG) IgG4-Related Disease (IgG4-RD) Dazodalibep Sjögren’s Syndrome(1,2) Focal Segmental Glomerulosclerosis (FSGS)(2) Daxdilimab Systemic Lupus Erythematosus (SLE) (3) Alopecia Areata (AA) Discoid Lupus Erythematosus (DLE) Lupus Nephritis (LN) Dermatomyositis and Anti-Synthetase Inflammatory Myositis HZN-825 Diffuse Cutaneous Systemic Sclerosis (dcSSc) Idiopathic Pulmonary Fibrosis (IPF) ADX-914 Atopic Dermatitis(4) Additional Autoimmune Disease(2,4) TEPEZZA Active TED in Japan (OPTIC-J) Chronic/Low Clinical Activity Score (CAS) TED in Japan Subcutaneous Administration HZN-1116 Autoimmune Diseases HZN-457 Next-Gen Uncontrolled Gout(5) Alpine Autoimmune Diseases(5) HemoShear Novel Gout Targets(5) Medicine/Candidate Program/Potential Indication Preclinical Phase 1 Phase 2 Phase 3 Three Phase 3 Clinical Development Programs Provide a Pathway to Additional Revenue Growth Beyond Our 3 Key Growth Drivers UPLIZNA in MG UPLIZNA in IgG4-RD Dazodalibep in Sjögren's Syndrome 3 Additional Phase 4 Programs: TEPEZZA in chronic/low CAS TED; KRYSTEXXA shorter infusion duration; KRYSTEXXA monthly dosing

UPLIZNA Sets a New Standard for Rare and Severe B-Cell Mediated Disorders CD19: Cluster of differentiation 19. | FCGR3A = Fc gamma receptor IIIa. Targeted and sustained depletion of CD19+ B cells, including plasmablasts and some plasma cells Glycoengineered design delivers consistent efficacy, even in patients with genetic variation in FCGR3A that reduces efficacy of previous generation monoclonal antibodies The humanized structure helps to decrease immunogenicity, improve tolerability and reduce infusion reaction risk Convenient 6-month dosing interval minimizes patient impact and enables long-term adherence Mechanism of Action Video Link Humanized F(ab) portion Optimized for human CD19 binding Afucosylated Fc portion

UPLIZNA is in Phase 3 Development for Two Additional Immune-Mediated Diseases Where B-Cell Dysregulation Plays an Important Role IgG4-Related Disease (IgG4-RD) Chronic, serious autoimmune fibro-inflammatory disease often affecting multiple organs, such as pancreas, salivary glands, kidneys Symptoms depend on which organs are affected, and can result in permanent organ damage Prevalence: ~20-40K in the U.S.(1) Significant unmet need; potential to be first FDA-approved therapy Phase 3 topline data expected in 2024 Myasthenia Gravis (MG) A chronic, rare autoimmune neuromuscular disorder Symptoms include weakness in voluntary muscles, especially those that control the eyes, mouth, throat and limbs Prevalence: ~55K in the U.S.(1) Potential for differentiation based on unique MOA and convenient, predictable 6-month dosing Phase 3 topline data expected in 2024 IgG4: Immunoglobulin G4. | MOA: Mechanism of action. (1) Horizon estimate.

The CD40/CD40L pathway is implicated in many autoimmune diseases including Sjögren’s syndrome CD40L drives inflammation through its interaction with CD40R which is expressed on several tissues in the salivary gland, spleen, kidney, joint, gut and skin Dazodalibep was designed as a next-generation CD40L antagonist blocking the CD40 pathway and undesired immune responses that lead to the development of autoimmune diseases Mechanism of Action Video Link CD40: Cluster of differentiation 40. | CD40L: Cluster of differentiation 40 ligand. | CD40R: Cluster of differentiation 40 receptor. Plasmablast Autoantibodies T cell Antigen Presenting Cell (APC) T cell T cell B cell Memory B cell B cell CD40L CD40 Dazodalibep Dazodalibep is a CD40L Antagonist Designed to Block a Central Pathway Involved in Many Autoimmune and Inflammatory Diseases

Chronic, systemic autoimmune disease attacking the salivary and tear (exocrine) glands, with severe cases also involving multiple organ systems Disease manifestations include dry eyes, dry mouth, arthritis and kidney or lung dysfunction Prevalence: ~250K-350K patients with Sjögren’s syndrome in the U.S.; OUS prevalence similar in size as U.S. Significant unmet need: No FDA-approved disease modifying treatments Current treatments: palliative care (artificial tears, medicines for dry mouth); topical cyclosporine; steroids/immunosuppressants used off-label as needed to manage systemic symptoms Sjögren’s Syndrome Dazodalibep is in Phase 3 Development for Sjögren’s Syndrome Following Strong Phase 2 Results Moderate-to-Severe Systemic Disease Activity (Pop. 1): ESSDAI score of ≥ 5, representing extraglandular organ involvement Systemic clinical manifestations in one or more organ systems in addition to the traditional Sjogren’s manifestations Two Distinct Patient Populations Moderate-to-Severe Symptomatology (Pop. 2): ESSPRI score of ≥ 5, indicative of significant symptomatic burden, and an ESSDAI score of < 5, representing limited extraglandular organ involvement Three domains of ESSPRI measure dryness, fatigue and pain OUS: Outside the United States, defined as prevalence for France, Germany, Italy, Spain, United Kingdom and Japan. | EULAR: European League Against Rheumatism | ESSDAI: EULAR Sjögren’s Syndrome Disease Activity Index: A Sjögren’s specific disease activity index composed of 12 system domains. | ESSPRI: EULAR Sjögren’s Syndrome Patient Reported Index: Patient reported index composed of three questions assessing dryness, fatigue and pain.

Reduction in ESSDAI Score at Day 169 Dazodalibep Clinical Trial in Sjögren's Syndrome is the Only Phase 2 Trial to Meet Primary Endpoint in Both Patient Populations EULAR: European League Against Rheumatism | ESSDAI: EULAR Sjögren’s Syndrome Disease Activity Index: A Sjögren’s specific disease activity index composed of 12 system domains. | ESSPRI: EULAR Sjögren’s Syndrome Patient Reported Index: Patient reported index composed of three questions assessing dryness, fatigue and pain. 4.1 +2.2 6.3 p=0.017 Population 1: Primary Endpoint Moderate-to-Severe Systemic Disease Activity (ESSDAI ≥ 5) Population 2: Primary Endpoint Moderate-to-Severe Symptomatology (ESSPRI ≥ 5, ESSDAI < 5) Reduction in ESSPRI Score at Day 169 0.53 +1.27 1.8 p=0.0002 ESSDAI results: All ESSDAI responder analyses (pre-specified and post-hoc) favored dazodalibep over placebo, with greater numerical differences for the highest levels of response (shown on slide 29) ESSPRI results: Patients treated with dazodalibep experienced numerically greater improvements in ESSPRI score and fatigue compared to those who received placebo at Day 169 Safety profiles were similar between the groups ESSPRI results: Statistically significant improvements in dazodalibep patients across the three domains of ESSPRI measuring dryness, fatigue and pain versus placebo (shown on slide 30) Additional ESSPRI results: Significantly more dazodalibep patients achieved a clinically meaningful ≥ 1-point (or ≥ 15%) reduction in ESSPRI scores versus placebo (66.7% versus 32.7%, respectively, p-value=0.0008) Safety profiles were similar between the groups

All ESSDAI Responder Analyses Favored Dazodalibep Over Placebo, With Greater Numerical Differences for the Highest Levels of Response ESSDAI [3], ESSDAI [4], ESSDAI [5] and ESSDAI [6] response defined as a decrease of at least 3, 4, 5, or 6 points, respectively, from baseline in the ESSDAI at Day 169 without premature discontinuation from the study and without receiving rescue therapy. *ESSDAI [5] and ESSDAI [6] analyses performed post-hoc. ESSDAI: EULAR Sjögren’s Syndrome Disease Activity Index. | EULAR: European Alliance of Associations for Rheumatology. | Analyzed using a logistic regression model. Dazodalibep (n=36) Placebo (n=37) p=0.3283 Dazodalibep (n=36) Placebo (n=37) p=0.1823 Dazodalibep (n=36) Placebo (n=37) p=0.0449 Dazodalibep (n=35) Placebo (n=35) p=0.0462 Population 1: ESSDAI Results Moderate-to-Severe Systemic Disease Activity (ESSDAI ≥ 5)

Dazodalibep Demonstrated Statistically Significant Improvements in the Three Domains of ESSPRI At Day 169 ESSPRI: EULAR Sjögren’s Syndrome Patient Reported Index: Patient reported index composed of three questions assessing dryness, fatigue and pain. | Data plotted by study visit. Change from baseline measured in least-squares mean, analyzed using MMRM. Dazodalibep (n=51) Placebo (n=53) p=0.0066 Dazodalibep (n=51) Placebo (n=53) p=0.0022 Dazodalibep (n=51) Placebo (n=53) p=0.0010 Population 2: ESSPRI Results Moderate-to-Severe Symptomatology (ESSPRI ≥ 5, ESSDAI < 5)

Urea cycle disorders (UCDs) Nephropathic cystinosis (NC) Chronic granulomatous disease (CGD) Indication U.S. Market(3) ~2,600 people with UCDs ~1,000 diagnosed population ~500-600 diagnosed patients ~400-450 diagnosed patients on cystine-depleting therapy ~1,600 people with CGD Rare and life-threatening genetic diseases resulting in the body’s inability to remove ammonia from the blood stream Can cause hyperammonia which can lead to intellectual disability, seizures, coma or death(1)(2) Rare and life-threatening, progressive, multisystem metabolic disorder Without cysteamine-depleting treatment, high intracellular cystine concentrations can occur in virtually all organs and tissues, leading to irreversible cellular damage, progressive multi-organ failure and death A life-threatening inherited primary immunodeficiency disease that limits the body’s ability to fight off certain pathogens Patients have increased susceptibility to severe and recurrent bacterial and fungal infections, along with the formation and development of granulomas in most organs Brand Strategy Conversion from older-generation nitrogen-scavengers to RAVICTI Increase awareness to position RAVICTI as first-line therapy Increase awareness and diagnosis of UCDs Conversion from older-generation cysteamine-depleting therapy to PROCYSBI Increase awareness to position PROCYSBI as first-line therapy Increase persistence of and adherence to treatment Increase awareness and diagnosis of CGD Drive adoption of “triple prophylaxis” therapy – immunomodulation (IFNg) + antifungal + antibiotic Increase persistence of and adherence to treatment (1) Summar, 2001. (2) Haeberle, 2019. (3) Horizon estimates. Rare Disease Medicines Durable Franchise That Addresses Serious Rare Diseases

Composition of matter patent to 2024 and method of treatment patent to 2039 Biologic Exclusivity to 2032 Orphan Drug Exclusivity to 2027 Patent estate extends to 2030 Composition of matter patent to 2026 Composition of matter patent to 2034 with patent term extension(1) Biologic Exclusivity to 2032 Settled Par (first-filer) litigation with right to market July 1, 2025 Settled with subsequent generic filers with the right to market 180 days after Par Patent estate extends to 2036 Orphan Drug Exclusivity: U.S. 2023-2025 Settled Lupin (first-filer on PROCYSBI capsules) litigation with right to market on March 31, 2030 (1) Patent term extension petition currently pending in USPTO. Our Portfolio Is Supported by Our Intellectual Property Portfolio

We make health a priority, not a privilege Access to Medicines and Our Patient-Centric Focus Key ESG Factors for Horizon: Overview ESG at Horizon is Overseen by the Board’s Nominating and Corporate Governance Committee We employ strong corporate governance principles and practices Our Governance We build healthier communities, urgently and responsibly; ethics and integrity are core to all we do Our Purpose and Our Focus on Ethics and Integrity We invest in our culture and are consistently recognized for our engaged and diverse workforce Engaged, Award-Winning Corporate Culture; Commitment to Diversity We go to incredible lengths at Horizon to impact lives and make the world a better place. Our mission is simple and powerful: to improve people’s lives. The work we do benefits the patients who use our medicines, their caregivers and treating physicians – and it also benefits all of us who work at Horizon, contributing to our longer-term success and sustainability. We work rigorously to ensure the safety and quality of our medicines Our Product Supply Chain We conduct our business in a responsible way that minimizes environmental impacts Minimizing Environmental Impacts

Reconciliations of GAAP to Non-GAAP Measures

Note Regarding Use of Non-GAAP Financial Measures Horizon provides certain non-GAAP financial measures, including EBITDA, or earnings before interest, taxes, depreciation and amortization, adjusted EBITDA, non-GAAP net income, non-GAAP diluted earnings per share, non-GAAP operating income and certain other non-GAAP income statement line items, each of which include adjustments to GAAP figures. These non-GAAP measures are intended to provide additional information on Horizon’s performance, operations, expenses, profitability and cash flows. Adjustments to Horizon’s GAAP figures exclude, as applicable, acquisition and/or divestiture-related costs, manufacturing facility start-up costs, restructuring and realignment costs, as well as non-cash items such as share-based compensation, inventory step-up expense, depreciation and amortization, non-cash interest expense, goodwill and long-lived assets impairment charges, gain (loss) on equity security investments and sales of assets, and other non-cash adjustments. Certain other special items or substantive events may also be included in the non-GAAP adjustments periodically when their magnitude is significant within the periods incurred. Horizon maintains an established non-GAAP cost policy that guides the determination of what costs will be excluded in non-GAAP measures. Horizon believes that these non-GAAP financial measures, when considered together with the GAAP figures, can enhance an overall understanding of Horizon’s financial and operating performance. The non-GAAP financial measures are included with the intent of providing investors with a more complete understanding of the Company’s historical and expected financial results and trends and to facilitate comparisons between periods and with respect to projected information. In addition, these non-GAAP financial measures are among the indicators Horizon’s management uses for planning and forecasting purposes and measuring the Company's performance. These non-GAAP financial measures should be considered in addition to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP. The non-GAAP financial measures used by the Company may be calculated differently from, and therefore may not be comparable to, non-GAAP financial measures used by other companies.

GAAP to Non-GAAP Reconciliation EBITDA and Adjusted EBITDA – Three and Six Months Ended June 30, Twelve Months Ended December 31, 2022 $ in thousands

GAAP to Non-GAAP Reconciliation Operating Income – Three and Six Months Ended June 30 $ in thousands

GAAP to Non-GAAP Reconciliation Non-GAAP Net Income – Three and Six Months Ended June 30 $ in thousands

GAAP to Non-GAAP Reconciliation Non-GAAP Earnings Per Share – Basic and Diluted – Three and Six Months Ended June 30